Latest News of ENDP
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
By MarketWatch |
1 week ago
Merck & Co. and Daiichi Sankyo announced success in a late-stage lung cancer study with their drug candidate, patritumab deruxtecan....
Arrowhead to file NDA after pivotal rare disease trial meets all endpoints
By Yahoo! Finance |
3 weeks ago
Arrowhead Pharmaceuticals plans to submit a new drug application (NDA) to the FDA for its lead candidate, plozasiran, after successful results from the Phase III Palisade trial in patients with famili...
Jazz Pharmaceuticals's CBD Trial Misses Primary Endpoint
By MarketWatch |
1 month ago
Jazz Pharmaceuticals's trial of CBD for seizures in Japanese pediatric patients with certain diseases did not meet its primary goal. The company plans to collect more data and discuss a new drug appli...
-
BioNTech's cancer drug meets primary endpoint in Phase 2 trial
By Yahoo! Finance | 2 months agoBioNTech's cancer drug candidate BNT111 showed promising results in a Phase 2 trial for advanced melanoma patients, with a significant improvement in response rates when combined with a checkpoint inh...
-
Innovent's Phase III trial of type 2 diabetes treatment meets endpoints
By Yahoo! Finance | 2 months agoInnovent Biologics reports positive Phase III trial results of mazdutide for treating type 2 diabetes in Chinese patients....
-
EDAP TMS: Study of Endometriosis Treatment Missed Endpoint But Will Continue
By MarketWatch | 2 months agoEDAP TMS's Phase 3 study on robotic therapy for endometriosis didn't meet its acute pain reduction goal at three months but will continue. The company remains optimistic about the therapy's benefits b...
-
Roche's Phase II/III NSCLC treatment trial fails to meet primary endpoints
By Yahoo! Finance | 2 months agoRoche's Phase II/III SKYSCRAPER-06 trial of tiragolumab, Tecentriq, and chemotherapy for non-squamous NSCLC did not meet primary endpoints. The study will be stopped, with findings shared with health ...
-
More endpoints met in Insmed's Phase III brensocatib trial
By Yahoo! Finance | 2 months agoInsmed's Phase III ASPEN trial data reveals brensocatib's effectiveness in reducing lung function decline in bronchiectasis patients. Positive results support potential approval as a chronic treatment...
-
INmune Bio's unique Alzheimer's trial endpoint receives validation
By Yahoo! Finance | 3 months agoINmune Bio's AD02 trial for Alzheimer's disease, using TNF XPro with EMACC as the primary endpoint, shows positive results after FDA clinical hold. The trial's efficacy in assessing cognitive function...
-
Pfizer's Phase III DMD gene therapy trial misses primary endpoint
By Yahoo! Finance | 3 months agoPfizer's Phase III trial of gene therapy for Duchenne muscular dystrophy in young boys did not meet its primary endpoint of improving motor function. Despite this, the therapy's safety profile was man...